ROBERT F GAGEL to Proto-Oncogene Proteins
This is a "connection" page, showing publications ROBERT F GAGEL has written about Proto-Oncogene Proteins.
Connection Strength
1.279
-
Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004 Aug; 89(8):4142-5.
Score: 0.129
-
Lessons learned from the management of a rare genetic cancer. N Engl J Med. 2003 Oct 16; 349(16):1566-8.
Score: 0.122
-
Promiscuity of pre-mRNA spliceosome-mediated trans splicing: a problem for gene therapy? Hum Gene Ther. 2001 Jul 20; 12(11):1429-41.
Score: 0.105
-
Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. 1999 Aug 15; 59(16):3911-4.
Score: 0.091
-
A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes. 1999 Feb; 13(1):77-9.
Score: 0.088
-
Mutational analysis of the GDNF/RET-GDNFR alpha signaling complex in a kindred with vesicoureteral reflux. Hum Genet. 1998 Apr; 102(4):474-8.
Score: 0.083
-
Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1996 Oct; 81(10):3740-5.
Score: 0.075
-
RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Sep; 82(3):288-94.
Score: 0.075
-
ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation. Endocrinology. 1996 May; 137(5):1509-11.
Score: 0.073
-
Putting the bits and pieces of the RET proto-oncogene puzzle together. Bone. 1995 Aug; 17(2 Suppl):13S-16S.
Score: 0.069
-
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab. 1995 Jul; 9(3):609-30.
Score: 0.069
-
A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis. J Biol Chem. 2015 May 01; 290(18):11749-61.
Score: 0.067
-
Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract. 2008 Dec; 14(9):1108-14.
Score: 0.044
-
Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002 Jun; 137(6):641-7.
Score: 0.028
-
Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene. 2001 Nov 22; 20(53):7809-11.
Score: 0.027
-
[Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Rev Med Chil. 2001 Jul; 129(7):713-8.
Score: 0.026
-
Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 2000 Nov 15; 60(22):6223-6.
Score: 0.025
-
Screening for MEN1 mutations in patients with atypical endocrine neoplasia. Surgery. 1999 Dec; 126(6):1097-103; discussion 1103-4.
Score: 0.023
-
Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2. Horm Metab Res. 1997 Mar; 29(3):135-7.
Score: 0.019
-
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996 Nov 20; 276(19):1575-9.
Score: 0.019
-
The abnormal pentagastrin test. Clin Endocrinol (Oxf). 1996 Feb; 44(2):221-2.
Score: 0.018
-
Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery. 1996 Dec; 120(6):1064-70; discussion 1070-1.
Score: 0.005